N. Goel

发表

Let’s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting

M. D. de Wit, W. Campbell, L. Coates, 2016, The Journal of Rheumatology.

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

N. Goel, V. Strand, J. Vencovský, 2008, Annals of the rheumatic diseases.

N. Goel, K. Chance, Kamali Chance, 2016, Rheumatology.

Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report

M. Suarez‐Almazor, N. Goel, V. Strand, 2017, The Journal of Rheumatology.

Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12

N. Goel, M. Boers, D. van Schaardenburg, 2016, The Journal of Rheumatology.

Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group

Christie M. Bartels, P. Tugwell, V. Welch, 2017, The Journal of Rheumatology.

Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group.

M. Suarez‐Almazor, N. Goel, V. Strand, 2022, Seminars in arthritis and rheumatism.

Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative.

M. Suarez‐Almazor, P. Tugwell, N. Goel, 2021, Seminars in arthritis and rheumatism.

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.

N. Goel, J. Vencovský, E. Choy, 2012, Rheumatology.

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

N. Goel, V. Strand, J. Vencovský, 2008, Annals of the rheumatic diseases.

Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures

P. Tugwell, V. Welch, J. Jull, 2015, The Journal of Rheumatology.

Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11

L. Coates, D. Gladman, N. Goel, 2014, The Journal of Rheumatology.

Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.

N. Goel, D. M. van der Heijde, V. Strand, 2012, Rheumatology.

AB0786 Systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a grappa-omeract initiative

A. Ogdie, A. Orbai, W. Tillett, 2017 .

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials

B. Shea, M. D. de Wit, W. Campbell, 2016, Annals of the rheumatic diseases.

Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course

N. Goel, J. Reveille, G. Alarcón, 1998 .

Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture.

N. Goel, J. Reveille, G. Alarcón, 1998, Arthritis and rheumatism.

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.

G. Molenberghs, B. Ratitch, N. Goel, 2019, Therapeutic innovation & regulatory science.

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials

N. Goel, D. M. van der Heijde, D. Furst, 2016, Arthritis care & research.

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.

M. Dougados, N. Goel, P. Emery, 2012, Rheumatology.

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.

N. Goel, J. Reginster, A. Laslop, 2011, Rheumatology.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

B. Shea, M. D. de Wit, W. Campbell, 2017, The Journal of Rheumatology.

Recent Advances in Understanding of the Genetics of Antiphospholipid Syndrome

N. Goel, T. Ortel, 2017 .

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

M. D. de Wit, L. Coates, D. Gladman, 2022, Nature Reviews Rheumatology.

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects

N. Goel, R. Reeve, J. Caminis, 2018, Pharmacology research & perspectives.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials

P. Tugwell, B. Shea, M. D. de Wit, 2018, The Journal of Rheumatology.

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative.

L. Coates, D. Gladman, A. Ogdie, 2021, Seminars in arthritis and rheumatism.

Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.

N. Goel, J. Curtis, M. Weinblatt, 2011, Arthritis and rheumatism.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

M. D. de Wit, L. Coates, D. Gladman, 2022, Nature Reviews Rheumatology.

The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates

M. D. de Wit, L. Coates, D. Gladman, 2020, The Journal of Rheumatology. Supplement.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group

M. D. de Wit, L. Coates, D. Gladman, 2017, The Journal of Rheumatology.

OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021

L. Coates, D. Gladman, C. Lindsay, 2021 .

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report

M. D. de Wit, L. Coates, D. Gladman, 2019, The Journal of Rheumatology.

Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.

N. Goel, E. S. St. Clair, D. Lynch, 1995, Arthritis and rheumatism.

Mechanical sensation and pain thresholds in patients with chronic arthropathies.

N. Goel, K. Westlund, T. McNearney, 2003, The journal of pain : official journal of the American Pain Society.

Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance.

S. Kingsmore, N. Goel, C. Amos, 1999, Arthritis and rheumatism.

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

G. Molenberghs, B. Ratitch, N. Goel, 2020, Therapeutic Innovation & Regulatory Science.

Genetic analysis of multiplex rheumatoid arthritis families

I. Bruce, N. Goel, D. Zhu, 1999, Genes and Immunity.

Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis

M. Suarez‐Almazor, P. Tugwell, B. Shea, 2019, The Journal of Rheumatology.

Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.

N. Goel, M. Mayes, J. Reveille, 2007, Arthritis and rheumatism.

Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda

P. Tugwell, N. Goel, C. Terwee, 2015, The Journal of Rheumatology.

Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with self‐reported functional outcome in a large cohort study

N. Goel, J. Reveille, G. Alarcón, 1999 .

Conducting research in psoriatic arthritis: the emerging role of patient research partners

N. Goel, 2020, Rheumatology.

Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting

M. D. de Wit, D. Gladman, C. Lindsay, 2015, The Journal of Rheumatology.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting

B. Shea, M. D. de Wit, L. Coates, 2018, Journal of Rheumatology Supplement.

Perceived Functioning Has Ethnic-specific Associations in Systemic Sclerosis: Another Dimension of Personalized Medicine

N. Goel, M. Mayes, J. Reveille, 2009, The Journal of Rheumatology.

Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis

N. Goel, M. Panaccio, K. Hayes, 2021, Rheumatology and Therapy.

The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission

N. Goel, M. Boers, D. van Schaardenburg, 2015, Annals of the rheumatic diseases.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set

M. D. de Wit, L. Coates, D. Gladman, 2019, The Journal of Rheumatology. Supplement.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

M. D. de Wit, D. Gladman, A. Ogdie, 2017, Seminars in arthritis and rheumatism.

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

A. Gottlieb, L. Coates, D. Gladman, 2021, Therapeutic advances in musculoskeletal disease.

Enhancing patient research partner engagement: Research in psoriatic arthritis.

N. Goel, 2021, Best practice & research. Clinical rheumatology.

GRAPPA 2019 Project Report

L. Coates, D. Gladman, D. O'Sullivan, 2020, The Journal of Rheumatology. Supplement.

Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis

L. Coates, D. Gladman, A. Ogdie, 2020, The Journal of Rheumatology.

Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

A. Gottlieb, D. Gladman, N. Goel, 2019, The Journal of Rheumatology. Supplement.

The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative

B. Shea, L. Coates, D. Gladman, 2018 .

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA

N. Goel, J. Reginster, A. Laslop, 2011, Current medical research and opinion.

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group

M. D. de Wit, L. Coates, D. Gladman, 2021, The Journal of Rheumatology. Supplement.

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review.

L. Coates, D. Gladman, C. Lindsay, 2020, Seminars in arthritis and rheumatism.

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting

M. D. de Wit, D. Gladman, C. Lindsay, 2016, Journal of Rheumatology.

Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014

M. D. de Wit, D. Gladman, A. Ogdie, 2015, The Journal of Rheumatology.

Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting

M. D. de Wit, D. Gladman, Jana M James, 2014, The Journal of Rheumatology.

Outcomes Reported in Prospective Long‐Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review

M. Suarez‐Almazor, N. Goel, V. Strand, 2020, Arthritis care & research.

Neurotransmitter excitatory amino acids in synovial fluids demonstrate distinct temporal fluctuations in active arthritis

N. Goel, K. Westlund, T. McNearney, 2018 .

Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group.

J. Ioannidis, M. Suarez‐Almazor, P. Tugwell, 2021, Seminars in arthritis and rheumatism.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials

M. Suarez‐Almazor, P. Tugwell, N. Goel, 2019, The Journal of Rheumatology.

Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective

P. Tugwell, N. Goel, C. Terwee, 2015, The Journal of Rheumatology.

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.

G. Molenberghs, B. Ratitch, N. Goel, 2019, Therapeutic innovation & regulatory science.

SAT0395 RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS

B. Shea, L. Coates, D. Gladman, 2019, Saturday, 15 June 2019.

Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis

L. Coates, D. Gladman, C. Lindsay, 2021, The Journal of Rheumatology.

Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases.

N. Goel, J. Takeshita, K. Callis Duffin, 2022, The Journal of rheumatology.

The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France

M. D. de Wit, N. Goel, L. Gossec, 2018, Advances in Rheumatology.

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines

G. Molenberghs, B. Ratitch, N. Goel, 2020, Therapeutic Innovation & Regulatory Science.

SYSTEMATIC REVIEW OF MEASUREMENT PROPERTIES OF PATIENT REPORTED OUTCOME MEASURES IN PSORIATIC ARTHRITIS: A GRAPPA-OMERACT INITIATIVE

D. Gladman, A. Ogdie, A. Orbai, 2017 .

Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016

P. Tugwell, M. D. de Wit, N. Goel, 2017, Journal of Rheumatology.

Imaging With PET/CT of Diffuse CD8 T-Cell Infiltration of Skeletal Muscle in Patients With Inclusion Body Myositis

N. Goel, S. Greenberg, J. McConathy, 2023, Neurology.

FRI0346 Evaluating Differences in The Enrolled Populations of Randomized Clinical Trials of Systemic Lupus Erythematosus

N. Goel, M. Mackey, A. Duncan, 2016 .

Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014

M. D. de Wit, D. Gladman, A. Ogdie, 2015, The Journal of Rheumatology.

Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting

M. D. de Wit, D. Gladman, A. Ogdie, 2015, The Journal of Rheumatology.

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting

M. D. de Wit, D. Gladman, C. Lindsay, 2016, The Journal of Rheumatology.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

B. Shea, M. D. de Wit, L. Coates, 2017, The Journal of Rheumatology.

Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting

L. Coates, C. Lindsay, A. Ogdie, 2017, The Journal of Rheumatology.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group

M. D. de Wit, L. Coates, D. Gladman, 2017, The Journal of Rheumatology.

Let’s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting

M. D. de Wit, L. Coates, D. Gladman, 2016, The Journal of Rheumatology.

AB0794 CLINICAL TRIAL DISCRIMINATION OF PHYSICAL FUNCTION INSTRUMENTS FOR PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW

D. Gladman, C. Lindsay, A. Ogdie, 2020, Annals of the Rheumatic Diseases.

AB0794 CLINICAL TRIAL DISCRIMINATION OF PHYSICAL FUNCTION INSTRUMENTS FOR PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW

D. Gladman, C. Lindsay, A. Ogdie, 2020, Annals of the Rheumatic Diseases.

Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group

P. Tugwell, V. Welch, J. Jull, 2017, The Journal of Rheumatology.

Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016

P. Tugwell, M. D. de Wit, N. Goel, 2017, The Journal of Rheumatology.

Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

D. Gladman, N. Goel, R. Queiro-Silva, 2022, The Journal of Rheumatology.

Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group

M. Suarez‐Almazor, P. Tugwell, N. Goel, 2017, The Journal of Rheumatology.